Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

TSHA stock hub

Taysha Gene Therapies, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

TSHAis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

TSHA

In the news

Latest news · TSHA

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-97.3

P25 -105.6P50 -46.5P75 -3.1

ROIC-41.7

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All TSHA market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

205

Groups with data

Currency

USD

Showing 205 of 205 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001806310
Company name	Taysha Gene Therapies, Inc.
Country	United States
Country code	US
Cusip	877619106
Employees	99
Employees Change	26%
Employees Change Percent	35.62
Enterprise value	$1.7B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2020-09-24
Isin	US8776191061
Last refreshed	2026-05-10
Market cap	$2B
Market cap category	Small-Cap
Price	$6.81
Price currency	USD
Rev Per Employee	75,464.65x
Sector	Healthcare
Sic	2836
Symbol	TSHA
Website	https://www.tayshagtx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-6.64%
EV Sales Forward	675.04x
EV/Sales	234.09x
FCF yield	-5.74%
P/B ratio	7.86x
P/S ratio	261.94x
PS Forward	755.34x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	100%
Gross Profit	$7.5M
Gross Profit Growth	3.42%
Gross Profit Growth3 Y	1.2%
Net Income	$-129.9M
Net Income Growth Years	0%
Pretax Margin	-1,738.4%
Profit Per Employee	$-1.3M
ROA	-37.77
Roa5y	-36.37
ROCE	-47.3
ROE	-97.28
Roe5y	-186
ROIC	-41.72

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	258.74%
Cagr3y	112.85%
Cagr5y	-20.32%
EPS Growth Years	4
Revenue Growth	3.42x
Revenue Growth Years	1x
Revenue Growth3 Y	1.2x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.03
Assets	$300.4M
Cash	$276.6M
Current Assets	$282.3M
Current Liabilities	$20.1M
Debt	$68.6M
Debt Equity	$0.32
Equity	$211.9M
Interest Coverage	-2,501.2
Liabilities	$88.4M
Long Term Assets	$18.1M
Long Term Liabilities	$68.3M
Net Cash	$208M
Net Cash By Market Cap	$10.63
Net Cash Growth	278.48%
Net Debt Equity	$-0.98
Tangible Book Value	$211.9M
Tangible Book Value Per Share	$0.74
WACC	10.67

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	14.04
Net Working Capital	$-12.6M
Quick ratio	13.76
Working Capital	$262.2M
Working Capital Turnover	$0.04

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-32.5%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	258.42%
200-day SMA	4.46
3Y total return	864.86%
50-day SMA	5.2
50-day SMA vs 200-day SMA	50over200
5Y total return	-67.88%
All Time High	33.35
All Time High Change	-79.58%
All Time High Date	2021-01-19
All Time Low	0.5
All Time Low Change	1,262%
All Time Low Date	2023-06-26
ATR	0.42
Beta	1.23
Beta1y	2.83
Beta2y	2.63
Ch YTD	23.82
High	7.01
High52	7.3
High52 Date	2026-05-06
High52ch	-6.71%
Low	6.58
Low52	1.85
Low52 Date	2025-05-08
Low52ch	268.11%
Ma50ch	31.06%
Premarket Change Percent	0.45
Premarket Price	$6.7
Premarket Volume	5,334
Price vs 200-day SMA	52.66%
RSI	65.89
RSI Monthly	65.78
RSI Weekly	71.3
Sharpe ratio	1.8x
Sortino ratio	3.96
Total Return	-32.5%
Tr YTD	23.82
Tr1m	49.02%
Tr1w	7.58%
Tr3m	47.72%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	8
Analyst Count Top	4
Analyst Price Target Top	$12.25
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.1
Earnings Revenue Estimate	758,330x
Earnings Revenue Estimate Growth	-67.03x
Operating Income	$-132.6M
Operating margin	-1,774.4
Price target	$11.63
Price Target Change	$70.78
Price Target Change Top	$79.88

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	198,546,089%
Float Percent	69.09%
Net Borrowing	9,241,000
Shares Insiders	9.43%
Shares Institutions	76.59%
Shares Out	287,361,020
Shares Qo Q	2.61%
Shares Yo Y	32.5%
Short Float	19.6%
Short Ratio	12.83
Short Shares	13.54

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-127.9M
Average Volume	2,990,927.95x
Bv Per Share	0.74
CAPEX	$-384,000
Ch1m	49.02
Ch1w	7.58
Ch1y	258.4
Ch3m	47.72
Ch3y	864.9
Ch5y	-67.88
Ch6m	77.81
Change	2.1%
Change From Open	3.18
Close	6.67
Days Gap	-1.05
Depreciation Amortization	1,157,000
Dollar Volume	14,843,402.9
Earnings Date	2026-05-06
Earnings Time	bmo
EBIT	$-132.6M
EBITDA	$-131.4M
EPS	$-0.38
F Score	2
FCF	$-112.3M
FCF EV Yield	-6.42x
FCF Per Share	$-0.39
Financing CF	275,352,000
Fiscal Year End	December
Founded	2,019
Investing CF	-3,257,000
Ipr	-65.95
Iprfo	-69.39
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-06
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-03-19
Ma150	4.96
Ma150ch	37.41%
Ma20	6.28
Ma20ch	8.53%
Net CF	160,147,000
Next Earnings Date	2026-08-11
Open	6.6
Optionable	Yes
Position In Range	53.49
Post Close	6.81
Postmarket Change Percent	-0.88
Postmarket Price	$6.75
Ppne	15,605,000
Pre Close	6.67
Price Date	2026-05-08
Ptbv Ratio	9.23
Relative Volume	0.73x
Revenue	7,471,000x
SBC By Revenue	208.15x
Share Based Comp	15,551,000
Tr6m	77.81%
Us State	Texas
Volume	2,179,648
Z Score	2.67

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does TSHA pay a dividend?

Capital-return profile for this ticker.

Performance

TSHA stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns TSHA?

Insider, institutional, and short-interest positioning.

Institutional ownership

+76.6%

Float: +69.1% of shares outstanding

Insider ownership

+9.4%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

TSHA momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

65.9

Neutral momentum band

Price vs 200-day MA

+52.7%

50/200-day relationship not available

Beta (5Y)

1.23

More volatile than the market

Sharpe ratio

1.79

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About TSHA

Hub-level FAQ points readers to the deeper analysis pages.

What is the current TSHA stock rating?

Taysha Gene Therapies, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full TSHA analysis?

The full report lives at /stocks/TSHA/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for TSHA?

The latest report frames TSHA around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the TSHA page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.